Unlock stock picks and a broker-level newsfeed that powers Wall Street.
0.0001
0.0000
(0.00%)
At close: April 4 at 4:00:00 PM EDT
Breakdown
TTM
Total Revenue
23.3000
Operating Expense
3,573.8120
Operating Income
-3,550.5120
Net Non Operating Interest Income Expense
-119.2820
Other Income Expense
488.7700
Pretax Income
-3,181.0240
Net Income Common Stockholders
-3,310.1310
Diluted NI Available to Com Stockholders
-3,310.1310
Basic EPS
-0.61
Diluted EPS
-0.61
Basic Average Shares
5,425.2840
Diluted Average Shares
5,425.2840
Total Expenses
3,573.8120
Net Income from Continuing & Discontinued Operation
-3,181.0240
Normalized Income
-3,669.1570
Interest Expense
119.2820
Net Interest Income
-119.2820
EBIT
-3,061.7420
EBITDA
-2,972.5040
Reconciled Depreciation
89.2380
Net Income from Continuing Operation Net Minority Interest
-3,181.0240
Total Unusual Items Excluding Goodwill
488.1330
Total Unusual Items
488.1330
Normalized EBITDA
-3,460.6370
8/29/57232 - 1/5/2009
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CSBR Champions Oncology, Inc.
7.49
-8.32%
BNTC Benitec Biopharma Inc.
12.32
-5.30%
CGTX Cognition Therapeutics, Inc.
0.3542
-8.24%
CANF Can-Fite BioPharma Ltd.
1.4700
-2.65%
HOTH Hoth Therapeutics, Inc.
0.8399
-9.97%
RGLS Regulus Therapeutics Inc.
1.6850
-6.39%
DBVT DBV Technologies S.A.
6.50
-17.30%
ENTO Entero Therapeutics, Inc.
0.5090
+16.48%
PCSA Processa Pharmaceuticals, Inc.
0.3400
+6.75%
ALLK Allakos Inc.
0.3150
-1.56%